VTVT stock forecast, quote, news & analysis
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases... Show more
Why vTv Therapeutics (VTVT) Is Up +12% in the Last 30 Days
Key Takeaways
- vTv Therapeutics (VTVT) stock rose +12% over the past 30 days, driven by positive analyst coverage and participation in industry conferences.
- Over the past quarter, shares gained +19%, supported by an earnings beat, milestone funding from partnerships, and ongoing Phase 3 trial progress.
- Key factors include analyst initiations and reiterations with upside targets, $20 million in non-dilutive funding, and anticipation for cadisegliatin data.
- Biopharma sector sentiment and pipeline advancements in type 1 diabetes treatment bolstered investor confidence.
- Upcoming Phase 3 topline results in the second half of 2026 remain a major catalyst.
vTv Therapeutics (VTVT) Company Overview and Market Position
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule drug candidates for metabolic and inflammatory diseases. Its lead product candidate, cadisegliatin (also known as TTP399), is a potential first-in-class liver-selective glucokinase activator currently in a Phase 3 trial called CATT1 for the adjunctive treatment of type 1 diabetes (T1D). The company employs a streamlined business model centered on advancing its pipeline through clinical development and strategic partnerships, such as licensing agreements with Newsoara Biopharma and M42's IROS for expansion into type 2 diabetes (T2D) studies.
In the competitive biopharma landscape targeting unmet needs in diabetes care, vTv differentiates through its focus on oral therapies that address glycemic control without common side effects like hypoglycemia. Strong cash position from recent milestones and a narrow pipeline reduce dilution risk, explaining resilience amid volatility as investors price in Phase 3 potential.
vTv Therapeutics (VTVT) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, VTVT stock advanced +12%, closing at $40.45 from around $36.21. The movement was volatile, with intraday swings reflecting news flow, but featured a net uptrend amid higher trading volumes on key days.
For the past quarter, shares climbed +19% from approximately $34.11. Performance was trend-driven upward overall, punctuated by dips in early March before recovering on positive developments, trading within a broader range of $31 to $44.
What Drove VTVT Stock Price in the Last 30 Days
Several company-specific catalysts propelled VTVT's +12% gain. In mid-March, Evercore ISI Group initiated coverage with an Outperform rating and $44 price target, while BTIG reiterated Buy with a $49 target, highlighting the cadisegliatin Phase 3 potential. These upgrades boosted sentiment, coinciding with a sharp rebound from March lows around $33.
vTv's participation in the 38th Annual ROTH Conference on March 23 further elevated visibility, allowing management to update on trial enrollment and partnerships. Inducement grants announced on April 7 signaled talent retention amid growth. Broader biopharma optimism, tied to diabetes treatment demand, amplified these factors, driving steady buying despite daily fluctuations.
What Drove VTVT Stock Performance Over the Last Quarter
The +19% quarterly rise stemmed from sustained pipeline momentum and financial strengthening. On March 10, vTv reported Q4 2025 results, posting an EPS of -$0.58 that beat consensus estimates of -$1.04, alongside a $27 million full-year net loss but highlighting $20 million received in February 2026 from Newsoara under an amended licensing deal for phosphodiesterase type 4 inhibitors.
Progress in the CATT1 Phase 3 trial, with enrollment updates and topline data eyed for late 2026, underpinned gains. A December 2025 announcement of Phase 2 protocol submission for cadisegliatin in T2D with M42's IROS in the UAE—first patient dosing in Q1 2026—added geographic diversification. Institutional interest grew on these non-dilutive funding and regulatory milestones, outweighing volatility from market rotations.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots from a library of hundreds scanning thousands of tickers. These curated bots employ diverse strategies, including trend-following, mean reversion, and momentum plays across various timeframes, with performance metrics like win rate, profit factor, and Sharpe ratio displayed for transparency. Updated in real-time, the section highlights bots excelling in current market conditions, helping traders identify tools aligned with their risk tolerance and goals. Explore the page to discover bots potentially suited for stocks like VTVT and enhance your trading edge.
VTVT Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor CATT1 Phase 3 enrollment completion and topline results expected in the second half of 2026, as positive data could validate cadisegliatin's efficacy in T1D. Upcoming Q1 2026 earnings around May 7 will provide cash runway updates post-Newsoara milestone. Progress in the M42/IROS Phase 2 T2D trial, including first patient data, and any new partnerships or regulatory filings are key.
Macro factors like interest rates impacting biopharma funding and diabetes prevalence trends warrant attention. Risks include trial delays or adverse events, while catalysts encompass additional licensing deals or analyst revisions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
VTVT's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for VTVT turned positive on June 17, 2026. Looking at past instances where VTVT's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 17, 2026. You may want to consider a long position or call options on VTVT as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
VTVT moved above its 50-day moving average on June 18, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VTVT advanced for three days, in of 256 cases, the price rose further within the following month. The odds of a continued upward trend are .
VTVT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VTVT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.534) is normal, around the industry mean (20.056). P/E Ratio (0.000) is within average values for comparable stocks, (35.868). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.677). VTVT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (9.930) is also within normal values, averaging (361.304).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. VTVT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VTVT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage pharmaceutical holding company, which focuses on the discovery and development of human therapeutics
Industry Biotechnology